文献速递白血病

在FLT3-ITD急性髓系白血病中,米哚妥林加入化疗并继续单药维持治疗

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.
PubMed 文献 · Blood · 2018-12-18

一项2期假设生成试验纳入284例新诊断FLT3-ITD急性髓系白血病患者,评估米哚妥林联合强化化疗、异基因造血细胞移植及12个月单药维持治疗的可行性及对无事件生存的影响;诱导后完全缓解率76.4%,倾向评分加权分析显示米哚妥林显著改善无事件生存(HR 0.58,95%CI 0.48-0.70,P<.001)。

要点

  • 诱导后完全缓解(含CRi)率为76.4%,年轻患者75.8%,老年患者77.9%。
  • 倾向评分加权分析显示米哚妥林显著改善无事件生存(HR 0.58,95%CI 0.48-0.70,P<.001)。
  • 老年患者中米哚妥林同样显著改善无事件生存(HR 0.42,95%CI 0.29-0.61)。

核心结论

  • 在FLT3-ITD急性髓系白血病患者中,米哚妥林加入强化化疗并继续单药维持治疗可行,且与历史对照相比有利于改善无事件生存。

研究设计与样本

  • 一项2期假设生成试验,纳入284例18至70岁新诊断且中心确认FLT3-ITD的急性髓系白血病患者,其中年轻患者(18-60岁)198例,老年患者(61-70岁)86例。
  • 治疗方案为多靶点激酶抑制剂米哚妥林加入强化化疗,随后进行异基因造血细胞移植和12个月单药维持治疗。
  • 无事件生存与5项前瞻性试验中治疗的415例历史对照进行比较,采用倾向评分加权分析。
  • 研究注册号为NCT01477606。

主要发现

  • 诱导治疗后完全缓解率(包括血液学恢复不完全的完全缓解CRi)为76.4%,年轻患者为75.8%,老年患者为77.9%。
  • 达到CR/CRi的患者中多数(72.4%)接受了异基因造血细胞移植。
  • 97例(34%)患者开始维持治疗:75例在异基因造血细胞移植后,22例在大剂量阿糖胞苷巩固治疗后。
  • 异基因造血细胞移植后维持治疗的中位时间为9个月,大剂量阿糖胞苷巩固后为10.5个月;提前终止主要由于非复发原因(胃肠道毒性和感染)。
  • 年轻患者2年无事件生存率为39%(95%CI 33%-47%),总生存率为34%(95%CI 24%-47%);老年患者2年无事件生存率为53%(95%CI 46%-61%),总生存率为46%(95%CI 35%-59%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with acute myeloid leukemia (AML) and a FLT3 internal tandem duplication (ITD) have poor outcomes to current treatment. A phase 2 hypothesis-generating trial was conducted to determine whether the addition of the multitargeted kinase inhibitor midostaurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (alloHCT) and single-agent maintenance therapy of 12 months is feasible and favorably influences event-free survival (EFS) compared with historical controls. Patients 18 to 70 years of age with newly diagnosed AML and centrally confirmed FLT3-ITD were eligible: 284 patients were treated, including 198 younger (18-60 years) and 86 older (61-70 years) patients. Complete remission (CR) rate, including CR with incomplete hematological recovery (CRi) after induction therapy, was 76.4% (younger, 75.8%; older, 77.9%). The majority of patients in CR/CRi proceeded to alloHCT (72.4%). Maintenance therapy was started in 97 patients (34%): 75 after alloHCT and 22 after consolidation with high-dose cytarabine (HiDAC). Median time receiving maintenance therapy was 9 months after alloHCT and 10.5 months after HiDAC; premature termination was mainly a result of nonrelapse causes (gastrointestinal toxicity and infections). EFS and overall survival at 2 years were 39% (95% confidence interval [CI], 33%-47%) and 34% (95% CI, 24%-47%) and 53% (95% CI, 46%-61%) and 46% (95% CI, 35%-59%) in younger and older patients, respectively. EFS was evaluated in comparison with 415 historical controls treated within 5 prospective trials. Propensity score-weighted analysis revealed a significant improvement of EFS by midostaurin (hazard ratio [HR], 0.58; 95% CI, 0.48-0.70; P < .001) overall and in older patients (HR, 0.42; 95% CI, 0.29-0.61). The study was registered at www.clinicaltrials.gov as #NCT01477606.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2018. PMID: 30563875. doi:10.1182/blood-2018-08-869453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。